CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background: Pathogenic germline mutations in the CDKN2A tumor suppressor gene are rare and associated with highly penetrant familial melanoma and pancreatic cancer in non-Hispanic whites (NHW). To date, the prevalence and impact of CDKN2A rare coding variants (RCV) in racial minority groups remain poorly characterized. We examined the role of CDKN2A RCVs on the risk of pancreatic cancer among minority subjects. Methods: We sequenced CDKN2A in 220 African American (AA) pancreatic cancer cases, 900 noncancer AA controls, and 183 Nigerian controls. RCV frequencies were determined for each group and compared with that of 1,537 NHW patients with pancreatic cancer. Odds ratios (OR) and 95% confidence intervals (CI) were calculated for both a case–case comparison of RCV frequencies in AAs versus NHWs, and case–control comparison between AA cases versus noncancer AA controls plus Nigerian controls. Smaller sets of Hispanic and Native American cases and controls also were sequenced. Results: One novel missense RCV and one novel frameshift RCV were found among AA patients: 400G>A and 258_278del. RCV carrier status was associated with increased risk of pancreatic cancer among AA cases (11/220; OR, 3.3; 95% CI, 1.5–7.1; P = 0.004) compared with AA and Nigerian controls (17/1,083). Further, AA cases had higher frequency of RCVs: 5.0% (OR, 13.4; 95% CI, 4.9–36.7; P < 0.001) compared with NHW cases (0.4%). Conclusions: CDKN2A RCVs are more common in AA than in NHW patients with pancreatic cancer and associated with moderately increased pancreatic cancer risk among AAs. Impact: RCVs in CDKN2A are frequent in AAs and are associated with risk for pancreatic cancer. Cancer Epidemiol Biomarkers Prev; 27(11); 1364–70. ©2018 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ClinVar: improving access to variant interpretations and supporting evidence
Landrum, M. J., Lee, J. M., Benson, M., Brown, G. R., Chao, C., Chitipiralla, S., Gu, B., Hart, J., Hoffman, D., Jang, W., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1153 · Cited by 4,196
Predicting Functional Effect of Human Missense Mutations Using PolyPhen‐2
Adzhubei, I., Jordan, D. M., & Sunyaev, S. R. (2013) · Current Protocols in Human Genetics · doi:10.1002/0471142905.hg0720s76 · Cited by 3,705 · cited 1×
“In silico descriptive analyses were performed with SIFT (49) and PolyPhen2 (50) for the variants identified (insertions/deletions assumed deleterious by those tools are not annotated) when available but were not used for the final determination of variant status due to their imperfect specificity (51).”
MethodEvolution and functional impact of rare coding variation from deep sequencing of human exomes
Tennessen, J. A., Bigham, A. W., O’Connor, T. D., Fu, W., Kenny, E. E., Gravel, S., McGee, S., Do, R., Liu, X., Jun, G., et al. (2012) · Science · doi:10.1126/science.1219240 · Cited by 1,613 · cited 1×
“Further, among likely functional SNVs, the proportions of rare and intermediate frequency variants per individual are higher among African ancestry individuals compared with those of European ancestry (58).”
BackgroundThe Genetic Structure and History of Africans and African Americans
Tishkoff, S. A., Reed, F. A., Friedlaender, F. R., Ehret, C., Ranciaro, A., Froment, A., Hirbo, J. B., Awomoyi, A. A., Bodo, J.-M., Doumbo, O., et al. (2009) · Science · doi:10.1126/science.1172257 · Cited by 1,573 · cited 1×
“Secondly, African populations are evolutionarily the most ancestral among humans (56, 57); therefore, onemight postulate that the existence Table 2.”
BackgroundThe p16INK4a/CDKN2A tumor suppressor and its relatives
Ruas, M., & Peters, G. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(98)00017-1 · Cited by 911
Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16
Lukas, J., Parry, D., Aagaard, L., Mann, D. J., Bartkova, J., Strauss, M., Peters, G., & Bartek, J. (1995) · Nature · doi:10.1038/375503a0 · Cited by 899 · cited 2×
“Both p16 and p14 appear to suppress tumorigenesis (62, 63).”
BackgroundDeMichele, A., Clark, A. S., Tan, K. S., Heitjan, D. F., Gramlich, K., Gallagher, M., Lal, P., Feldman, M., Zhang, P., Colameco, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2258 · Cited by 343 · cited 1×
“Commonly mutated in somatic pancreatic tumors (16), CDKN2A's transcript p16 inhibits CDK4, a key function of cell-cycle regulation in pancreatic cancer (65) and CDK4/6 inhibitors have demonstrated strong activity in breast cancer (66), with recent FDA approvals of palbociclib and ribociclib, and some early evidence of…”
BackgroundFranco, J., Witkiewicz, A. K., & Knudsen, E. S. (2014) · Oncotarget · doi:10.18632/oncotarget.2270 · Cited by 207 · cited 1×
“Commonly mutated in somatic pancreatic tumors (16), CDKN2A's transcript p16 inhibits CDK4, a key function of cell-cycle regulation in pancreatic cancer (65) and CDK4/6 inhibitors have demonstrated strong activity in breast cancer (66), with recent FDA approvals of palbociclib and ribociclib, and some early evidence of…”
Background
Cited by
Cancer health disparities in racial/ethnic minorities in the United States
Zavala, V. A., Bracci, P. M., Carethers, J. M., Carvajal-Carmona, L., Coggins, N. B., Cruz-Correa, M. R., Davis, M., de Smith, A. J., Dutil, J., Figueiredo, J. C., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01038-6 · Cited by 912
Mirabello, L., Zhu, B., Koster, R., Karlins, E., Dean, M., Yeager, M., Gianferante, M., Spector, L. G., Morton, L. M., Karyadi, D., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0197 · Cited by 243
The Role of Inherited Pathogenic CDKN2A Variants in Susceptibility to Pancreatic Cancer
Kimura, H., Klein, A. P., Hruban, R. H., & Roberts, N. J. (2021) · Pancreas · doi:10.1097/mpa.0000000000001888 · Cited by 65
Kimura, H., Paranal, R. M., Nanda, N., Wood, L. D., Eshleman, J. R., Hruban, R. H., Goggins, M. G., Klein, A. P., The Familial Pancreatic Cancer Genome Sequencing Project, & Roberts, N. J. (2022) · eLife · doi:10.7554/elife.71137 · Cited by 23
Metadata
- Authors
- McWilliams, R. R., Wieben, E. D., Chaffee, K. G., Antwi, S. O., Raskin, L., Olopade, O. I., Li, D., Highsmith, W. E., Colon-Otero, G., Khanna, L. G., Permuth, J. B., Olson, J. E., Frucht, H., Genkinger, J., Zheng, W., Blot, W. J., Wu, L., Almada, L. L., Fernandez-Zapico, M. E., Sicotte, H., Pedersen, K. S., & Petersen, G. M.
- Venue
- Cancer Epidemiology, Biomarkers & Prevention
- Published
- 2018-11-01
- Volume
- 27
- Issue
- 11
- Pages
- 1364-1370
- ISSN
- 1055-9965 (ISSN-L)
- 1538-7755
- OpenAlex
- W2884431269
- Cited by
- 37
- References
- 8
- FWCI
- 1.10
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations. https://app.cochat.ai/papers/10.1158/1055-9965.epi-17-1065
- The paper
- McWilliams, R. R., Wieben, E. D., Chaffee, K. G., Antwi, S. O., Raskin, L., Olopade, O. I., Li, D., Highsmith, W. E., Colon-Otero, G., Khanna, L. G., Permuth, J. B., Olson, J. E., Frucht, H., Genkinger, J., Zheng, W., Blot, W. J., Wu, L., Almada, L. L., Fernandez-Zapico, M. E., . . . Petersen, G. M. (2018). CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations. Cancer Epidemiology, Biomarkers & Prevention. https://doi.org/10.1158/1055-9965.epi-17-1065
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.